40311-72-6

Basic information

• Product Name: ethyl 2-(2,6-dichlorophenoxy)acetate
• Synonyms: ethyl 2-(2,6-dichlorophenoxy)acetate;Ethyl 2,6-dichlorophenyloxy acetate;ethyl (2,6-dichlorophenoxy)acetate
• CAS NO: 40311-72-6
• Molecular Formula: C₁₀H₁₀Cl₂O₃
• Molecular Weight: 249.0906
• Mol File: 40311-72-6.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 2-(2,6-dichlorophenoxy)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(2,6-dichlorophenoxy)acetate(40311-72-6)
• EPA Substance Registry System: ethyl 2-(2,6-dichlorophenoxy)acetate(40311-72-6)

Safety Data

• Hazardous Substances Data: 40311-72-6(Hazardous Substances Data)

Upstream product

• 3336-41-2 3,5-dichloro-4-hydroxybenzoic acid 
• 105-39-5 chloroacetic acid ethyl ester 
• 87-65-0 2,6-Dichlorophenol 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 575-90-6 2,6-dichlorophenoxyacetic acid 
• 15307-79-6 diclofenac sodium 
• 47066-13-7 N,N-Diethyl-N'-<(2,5-dichlor-phenoxy)-acetyl>-ethylendiamin 

Relevant articles and documents

Synthesis process of diclofenac sodium

The invention provides a synthesis process of diclofenac sodium, which is obtained by acylation reaction of o-aminobenzene acetate with 2 and 6 - dichlorophenoxy acetic acid respectively and acylation with chlorobenzoyl chloride followed by nucleophilic substitution with 2, 6 - dichlorophenol or 2 and 6 -dichlorophenol. Is hydrolyzed to give sodium diclofenac sodium. The synthesis process is simplified, the reaction condition is mild, and the yield and industrial popularization and application are facilitated.

The synthesis and evaluation of phenoxyacylhydroxamic acids as potential agents for Helicobacter pylori infections

Two series of ω-phenoxy contained acylhydroxamic acids as novel urease inhibitors were designed and synthesized. Biological activity evaluations revealed that ω-phenoxypropinoylhydroxamic acids were more active than phenoxyacetohydroxamic acids. Out of these compounds, 3-(3,4-dichlorophenoxy)propionylhydroxamic acid c24 showed significant potency against urease in both cell free extract (IC50 = 0.061 ± 0.003 μM) and intact cell (IC50 = 0.89 ± 0.05 μM), being over 450- and 120-fold more potent than the clinically prescribed urease inhibitor AHA, repectively. Non-linear fitting of experimental data (V-[S]) suggested a mixed-type inhibition mechanism and a dual site binding mode of these compounds.

1,3,4-Thiadiazol-2-amine Derivatives as Urotensin-II Receptor (UT) Antagonists

-